Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Sells $119,500.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This trade represents a 1.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Abeona Therapeutics Trading Up 5.2 %

Shares of Abeona Therapeutics stock traded up $0.25 during trading hours on Thursday, hitting $4.93. The company's stock had a trading volume of 803,391 shares, compared to its average volume of 418,799. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The company has a market capitalization of $239.03 million, a PE ratio of -1.83 and a beta of 1.70. The stock has a 50 day moving average of $5.38 and a 200 day moving average of $5.79.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19. Analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, March 24th. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. Finally, Oppenheimer initiated coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.50.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP bought a new position in Abeona Therapeutics during the 4th quarter worth about $520,000. Western Standard LLC raised its position in Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock valued at $11,610,000 after buying an additional 386,321 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $67,000. Twinbeech Capital LP bought a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $58,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $362,000. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.